BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act of 1934, as amended.

AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.

Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company’s proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates.

Viseon Inc. Announces Commercial Rollout and Initial Clinical Use of the 4K MaxView ® System for Advanced Digital Visualization during Minimally Invasive Spine Surgery.

Cyclo Therapeutics, Inc. today reported its financial results for the second quarter 2023.

Verasonics, Inc., the leader in research ultrasound, today announced it has enhanced the Vantage Research Ultrasound System with the introduction of the Verasonics Permissive License and new transducers, including a 15 MHz Row-Column Array and three general imaging transducers.

Biotricity Inc. today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new ‘dendranib’ nanomedicine candidate, at the International Society of Neuroimmunology Congress (ISNI) being held August 21 – 24, 2023 in Québec City, Canada.

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. financial markets.

Microbot Medical Inc. announces another step in its commitment to advance the commercialization processes of LIBERTY® with the signing of a manufacturing agreement with B.Y. Medimor Ltd.